Anti-amyloid immunotherapies have recently emerged as treatments for Alzheimer's disease. While these therapies have demonstrated efficacy in clearing amyloid-β and slowing cognitive decline, they have also been associated with amyloid-related imaging abnormalities (ARIA) which include both edema (ARIA-E) and hemorrhage (ARIA-H). Given that ARIA have been associated with significant morbidity in cases of antithrombotic or thrombolytic therapy, an understanding of mechanisms of and risk factors for ARIA is of critical importance for stroke care. We discuss the latest data regarding mechanisms of ARIA, including the role of underlying cerebral amyloid angiopathy, and implications for ischemic stroke prevention and management.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10931618 | PMC |
| http://dx.doi.org/10.3390/jcm13051245 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Challenges Derived from the Interaction Among Apolipoprotein E, Cholesterol, and Amyloid in Alzheimer's Disease.
Int J Mol Sci
November 2024
Departamento de Medicina, Facultad de Ciencias de la Salud, Universidad de Oviedo, ES-33006 Oviedo, Spain.
The isoform E4 of the Apolipoprotein E (ApoE) represents one of the strongest genetic risk factors for late-onset Alzheimer's disease (AD). ApoE has key roles in cholesterol transport and amyloid-β (Aβ) metabolism, which are both central to AD pathogenesis. The E4 isoform has been implicated in reduced cholesterol homeostasis, increased Aβ aggregation, and heightened tau phosphorylation, contributing to amyloid plaques and neurodegeneration.
View Article and Find Full Text PDFPearls and Oy-sters: A Patient on Lecanemab Newly Diagnosed With Atrial Fibrillation.
Neurology
December 2024
From the Department of Neurology (D.R., A.J.L.), Duke University School of Medicine, Durham; and Department of Surgery (B.A.Z.), Duke University, Durham, NC.
Article Synopsis
- * Her CHADS-VASc score of 6 indicates a high risk for stroke, typically necessitating anticoagulation treatment.
- * However, the use of anticoagulants is not recommended for patients on lecanemab, leading to a management dilemma that requires careful consideration and potential alternative solutions.
Passive anti-amyloid β immunotherapy in Alzheimer's disease-opportunities and challenges.
Lancet
November 2024
Department of Psychiatry and Psychotherapy, Medical Faculty, University of Cologne, Cologne, Germany; German Center for Neurodegenerative Diseases, Bonn, Cologne, Germany; Excellence cluster on cellular stress response in aging associated disease, University of Cologne, Cologne, Germany.
Article Synopsis
- The paper discusses the introduction of a new type of immunotherapy for Alzheimer's, focusing on the implications of how, when, and who should be treated with it.
- It reviews key clinical trial results for three treatments: aducanumab, lecanemab, and donanemab, along with recommendations for patient selection and safety monitoring.
- The authors highlight the shift from syndrome-based care to early, biomarker-guided treatments for Alzheimer's, emphasizing the need for changes in healthcare infrastructure to support this approach while also promising potential benefits in slowing disease progression.
Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability.
Nat Aging
November 2024
Translational Neuroimaging Laboratory, McGill Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal, McGill University, Montreal, Quebec, Canada.
Article Synopsis
- Recent advancements in Alzheimer's treatment now require verification of amyloid-β pathology using PET scans or cerebrospinal fluid, but blood tests could simplify this process.* -
- A study involving nearly 7,000 individuals identified that the plasma biomarker p-tau217 can reliably indicate amyloid-β pathology, especially in patients with probable Alzheimer’s dementia.* -
- The findings suggest that combining p-tau217 results with clinical assessments may allow for accurate diagnoses without the need for more invasive PET or CSF tests.*
Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy.
Brain
November 2024
Department of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Article Synopsis
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!